SCHEMBL336575

SCHEMBL336575

C1CC(N2CCNCC2)CCN1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.50
KMT2A Q03164 2/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HTR2C P28335 4/20 0.38
HTR2A P28223 2/20 0.38
L3MBTL3 Q96JM7 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CHRNB2 P17787 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRNB3 Q05901 1/20 0.36
CHRNA6 Q15825 1/20 0.36
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.35
GABRA1 P14867 1/20 0.35
TSHR P16473 1/20 0.35
GABRG2 P18507 1/20 0.35
NFKB1 P19838 1/20 0.35
GABRB3 P28472 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1400974 1.00 HTR6 (0.50) HTR6KMT2AHPGDSMN1; SMN2HTR2C
Hydrochloric Acid SCHEMBL31605521 0.97 KMT2A (0.52) HTR6KMT2AHPGDSMN1; SMN2HTR2C
SCHEMBL12190269 0.95
SCHEMBL63548 0.91
SCHEMBL894571 0.91
SCHEMBL3159987 0.91 HTR6 (0.41) HTR6KMT2AHPGDSMN1; SMN2HTR2C
SCHEMBL9558032 0.90 HTR6 (0.54) HTR6KMT2AHPGDSMN1; SMN2HTR2C
SCHEMBL5210940 0.90 HTR6 (0.43) HTR6KMT2AHPGDSMN1; SMN2HTR2C
SCHEMBL13250356 0.90 HTR6 (0.59) HTR6KMT2AHPGDSMN1; SMN2HTR2C
SCHEMBL336999 0.90 HTR6 (0.59) HTR6KMT2AHPGDSMN1; SMN2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116209475-A Therapeutic uses comprising a triple agonist long-acting conjugate or a combination of triple agonists 韩美药品株式会社 2023-06-02 CN claimed
CN-114425237-B Separation device and method for recycling crude ethylene glycol near-azeotropic impurities in polyester production process 中国石油化工股份有限公司 2023-05-02 CN claimed
CN-114425237-A Separation device and method for recovering crude ethylene glycol near-azeotropic impurities in polyester production process 中国石油化工股份有限公司 2022-05-03 CN claimed
CN-110965374-A Environment-friendly chlorine-resistant color fixing agent and preparation method thereof 王秋平 2020-04-07 CN claimed
CN-104098457-B Tetrahydrocurcumin analogue, preparation and application thereof 沈阳药科大学 2017-02-08 CN claimed
EP-4731309-A1 KRAS PROTEOLYSIS TARGETING CHIMERAS Paq Therapeutics Inc. (US) 2026-04-29 EP disclosed
US-20260092134-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery UNIV JOHNS HOPKINS (US) 2026-04-02 US disclosed
US-12582641-B2 Sulfur-containing compound based on glutarimide skeleton and application thereof SHANGHAITECH UNIVERSITY (CN) 2026-03-24 US disclosed
US-12527746-B2 Peptide/particle delivery systems THE JOHNS HOPKINS UNIVERSITY (US) 2026-01-20 US disclosed
EP-4642434-A2 LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2025-11-05 EP disclosed
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same Life Technologies Corporation (US) 2025-11-04 US disclosed
EP-4624466-A1 DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Innocure Therapeutics, Inc. (KR) 2025-10-01 EP disclosed
CN-1237183-A 6-0-substituted ketolides with antibacterial activity ABBOTT CO (US) 1999-12-01 CN disclosed
EP-0929563-A1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY Abbott Laboratories (US) 1999-07-21 EP disclosed
WO-1999016779-A1 3'-N-MODIFIED 6-O-SUBSTITUTED ERYTHROMYCIN KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 1999-04-08 WO disclosed
WO-1999011651-A2 3-DESCLADINOSE 6-O-SUBSTITUDED ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1999-03-11 WO disclosed
US-5866549-A MACROLIDE ANTIBIOTICS ABBOTT LABORATORIES (US) 1999-02-02 US disclosed
WO-1998009978-A1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 1998-03-12 WO disclosed
WO-1997042206-A1 6-O-SUBSTITUTED ERYTHROMYCIN COMPOUNDS AND METHOD FOR MAKING SAME ABBOTT LABORATORIES (US) 1997-11-13 WO disclosed
US-5215967-A AMINOACID DERIVATIVES INHIBITING RENIN MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1993-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527746-B2 Peptide/particle delivery systems VEGFA, IGF2BP2, MSTN HTR6 1747/4885KMT2A 4633/4885HPGD 2865/4885
US-12582641-B2 Sulfur-containing compound based on glutarimide skeleton and application thereof SUCNR1, SRD5A1, GLS HTR6 4051/4885KMT2A 4057/4885HPGD 2329/4885
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same SNRPA, NUDT21, SOAT2 HTR6 567/4885KMT2A 908/4885HPGD 2842/4885
US-20260092134-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery SLC43A1, SLC7A5, SLC7A1 HTR6 3171/4885KMT2A 4518/4885HPGD 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.